Skip to main content

Month: November 2020

XP Inc. Comments on November 26, 2020 Announcement by Itaú Unibanco Holding S.A.

SÃO PAULO, Brazil, Nov. 27, 2020 (GLOBE NEWSWIRE) — XP Inc., or XP, a leading, technology-driven platform and a trusted provider of low-fee financial products and services in Brazil, today commented, following the material fact released to the market on November 26, 2020, or the material fact, by Itaú Unibanco Holding S.A., or Itaú, in which Itaú communicated (i) the approval by its board of directors of the spin-off of its investment in XP, which will be segregated into a newly formed company, or Newco, whose only assets would be common shares of XP representing 41.05% of XP’s share capital, and (ii) the potential sale by Itaú of 5% of XP’s share capital, as previously communicated by Itaú on November 3, 2020, that XP has initiated studies on possible corporate structures that seek to maintain the interests of Itaú aligned with...

Continue reading

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™ (setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency

— Indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to POMC, PCSK1 or LEPR deficiency confirmed by genetic testing —— Approval supports company’s approach to address rare genetic diseases of obesity associated with an impaired MC4 receptor pathway —— People living with these rare genetic diseases of obesity struggle with insatiable hunger and excessive weight gain beginning at a young age —— Approval based on data from two 52-week open-label trials that demonstrated clinically meaningful and statistically significant weight loss and reduction of hunger —— Rare Pediatric Disease Priority Review Voucher issued to Rhythm by FDA —— Company to host conference call today at 9:30 a.m. ET —BOSTON, Nov. 27, 2020...

Continue reading

Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders

Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S.Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S., excluding rights to zuranolone in Japan, Taiwan and South KoreaSage Therapeutics to receive $1.525 billion in cash comprised of an upfront payment of $875 million and a $650 million equity investment as well as potential milestone payments, profit sharing and royaltiesSage to host conference call Monday, November 30 at 8:00 a.m. ETBiogen to host conference call Monday, November 30 at 9:00 a.m. ETCAMBRIDGE, Mass., Nov. 27, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop...

Continue reading

Peter Christiansen tiltræder som sportsdirektør i F.C. København

Senest 1. april 2021 tiltræder Peter Christiansen som sportsdirektør i F.C. København. Peter Christiansen vil referere til bestyrelsen for PARKEN Sport & Entertainment A/S.I perioden fra 2000 til 2005 spillede Peter Christiansen 120 kampe for F.C. København og har senest været ansat som sportschef i AGF A/S.Vedhæftet fil20-2020 Sportsdirektør

Continue reading

Sportschef stopper i AGF A/S

Aarhus, den 27. november 2020NASDAQ OMX Copenhagen A/SMeddelelse nr. 12 /2020Sportschef stopper i AGF A/SSportschef Peter Christiansen har i dag meddelt sin opsigelse, da han har underskrevet en aftale med F.C. København. AGF har på den baggrund ikke set andre muligheder end at suspendere ham med øjeblikkelig virkning.– Vi er meget ærgerlige over, at Peter Christiansen har valgt at stoppe i AGF. Han har haft stor betydning for den sportslige fremgang, vi har oplevet de seneste år, og jeg vil gerne takke ham for den store indsats, han har ydet for AGF. Vi skal nu finde en ny sportschef, og indtil vi har en permanent afløser på plads, har vi aftalt, at adm. direktør Jacob Nielsen overtager hans opgaver midlertidigt, siger Lars Fournais, bestyrelsesformand i AGF A/S.AGF har ikke yderligere kommentarer for nuværende.Med venlig hilsenAGF...

Continue reading

Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

SAN FRANCISCO and TOKYO, Nov. 27, 2020 (GLOBE NEWSWIRE) — FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, “FibroGen”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO® (roxadustat) for the treatment of anemia of chronic kidney disease (CKD) in adult patients not on dialysis. This marks the second approval in Japan for roxadustat through the Astellas and FibroGen collaboration, after the therapy was approved and launched for use in adult patients with anemia of CKD on dialysis last year.“We are delighted roxadustat is now approved in Japan for adults with anemia of CKD not on dialysis, as it allows even more patients to access this important new treatment option,” said Bernhardt G. Zeiher, M.D.,...

Continue reading

Pasinex Announces Extension To Nevada Option Agreement

TORONTO, Nov. 27, 2020 (GLOBE NEWSWIRE) — Pasinex Resources Limited (CSE: PSE) (FSE: PNX) (The “Company” or “Pasinex”) announces that they have reached an agreement with Cypress Development Corp. (“Cypress”) and Caliber Minerals Inc. to change the terms relating to the earn-in option agreement on the Gunman (formerly Spur) zinc exploration property in Nevada, USA.The agreement extends the deadline to complete the conditions to earn an initial 51% interest in the Gunman Project to December 31, 2022. It extends the deadline to complete the conditions to earn an additional 29% interest in the Gunman Project to December 31, 2024.As a condition precedent for the agreement’s effectiveness and as a binding and unconditional material obligation, Pasinex shall incur a minimum of US $200,000.00 of qualified exploration expenditures on or...

Continue reading

Bonduelle – Combined Shareholders’ Meeting December 3rd, 2020 – Adjournment

BONDUELLEA French SCA (Partnership Limited by Shares) with a capital of 56,942,095 Euros Head Office: La Woestyne, 59173 Renescure, France. Registered under number: 447 250 044 (Dunkerque Commercial and Companies Register)Villeneuve d’Ascq, November 27th,  2020Press ReleaseCombined Shareholders’ MeetingDecember 3rd, 2020Adjournment to December 17th, 2020In the absence of an order issued by the Government on the basis of Law No. 2020-1379 dated November 14th, 2020 on the state of health emergency in the context of Covid-19, making it possible to restore or adapt the conditions for holding shareholders’ meetings held as of December 1st, 2020, and taking into account the health context and the provisions decreed by the public authorities relating to the protection of populations, making it impossible for the shareholders to travel and for...

Continue reading

Bonduelle – Assemblée Générale Mixte 3 décembre 2020 – Ajournement

BONDUELLESociété en commandite par actions au capital de 56 942 095 €.Siège social : La Woestyne, 59173 Renescure.447 250 044 R.C.S. DunkerqueVilleneuve d’Ascq, le 27 novembre 2020CommuniquéASSEMBLEE GENERALE MIXTEDU 3 DECEMBRE 2020Ajournement au 17 décembre 2020En l’absence d’ordonnance prise par le Gouvernement sur la base de la loi n° 2020-1379 du 14 novembre 2020 sur l’état d’urgence sanitaire dans le contexte de la Covid-19, permettant de rétablir ou d’adapter les conditions de tenue des assemblées générales tenues à compter du 1er décembre 2020, et compte tenu du contexte sanitaire et des dispositions édictées par les pouvoirs publics relatifs à la protection des populations, conduisant à l’impossibilité pour les actionnaires de se déplacer et pour la société de recevoir et de réunir ses actionnaires physiquement, les actionnaires...

Continue reading

Harvia granted the Internationalization Award of the President of the Republic of Finland

Harvia Plc, the global market leader in sauna and spa, has received the Internationalization Award granted by the President of the Republic of Finland Sauli Niinistö. Harvia Plc, which has been awarded as a growth company, has developed in 70 years from a local stove manufacturer into an internationally renowned sauna and spa brand whose products and solutions are sold in more than 80 countries. The company’s determined internationalization strategy began in the 1990s.

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.